Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11477974 | 0.90 | CHRM2 (0.50) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5018926 | 0.87 | CTNNB1 (0.43) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4966560 | 0.84 | ACACB (0.41) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27695101 | 0.82 | CHRM2 (0.44) | KCNH2 | |
| SCHEMBL31061889 | 0.81 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL12775573 | 0.81 | TAAR1 (0.56) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10157959 | 0.81 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL13146598 | 0.81 | KCNH2 (0.44) | KCNH2 | |
| SCHEMBL3518923 | 0.81 | KDM4E (0.46) | KCNH2 | |
| SCHEMBL2562965 | 0.79 | TAAR1 (0.61) | TAAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-8466114-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8394772-B2 | Glycoside derivative and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20120196813-A1 | GLYCOSIDE DERIVATIVE AND USES THEREOF | NOVARTIS AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | KCNH2 1969/4885TAAR1 4361/4885SLC6A2 94/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | KCNH2 1969/4885TAAR1 4361/4885SLC6A2 94/4885 |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | KCNH2 1969/4885TAAR1 4361/4885SLC6A2 94/4885 |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | KCNH2 1969/4885TAAR1 4361/4885SLC6A2 94/4885 |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | KCNH2 2989/4885TAAR1 4707/4885SLC6A2 4170/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | KCNH2 2989/4885TAAR1 4707/4885SLC6A2 4170/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | KCNH2 1969/4885TAAR1 4361/4885SLC6A2 94/4885 |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | KCNH2 1969/4885TAAR1 4361/4885SLC6A2 94/4885 |
| US-20120196813-A1 | GLYCOSIDE DERIVATIVE AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | KCNH2 2018/4885TAAR1 4459/4885SLC6A2 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.